BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Capital Reinvestment Ratio
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Capital Reinvestment Ratio of 0.27x as of June 2024, meaning it reinvests 0% of its operating cash flow (€8.36 Billion) in capital expenditures (€2.23 Billion). Check BEXIMCO PHARMA.GDR REGS 1 (R2WA) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BEXIMCO PHARMA.GDR REGS 1 Capital Reinvestment Ratio (2022–2024)
This chart tracks BEXIMCO PHARMA.GDR REGS 1's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of BEXIMCO PHARMA.GDR REGS 1.
Annual Capital Reinvestment Ratio for BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Year-by-year Capital Reinvestment Ratio for BEXIMCO PHARMA.GDR REGS 1 from 2022 to 2024. See R2WA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | €8.36 Billion | €2.23 Billion | ▼ -40.0% |
| 2023 | 0.45x | €6.08 Billion | €2.71 Billion | ▼ -21.0% |
| 2022 | 0.56x | €5.21 Billion | €2.94 Billion | — |